Welcome to our dedicated page for Haoxi Health Technology SEC filings (Ticker: HAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Haoxi Health Technology Limited filings document foreign private issuer reporting for a China-based online marketing solutions provider with Class A ordinary shares listed on Nasdaq. Form 6-K reports furnish interim financial statements, management discussion and analysis, material-event disclosures and exhibits tied to the company’s operating results, liquidity and shareholder equity.
The company’s regulatory record also covers auditor changes, board composition, shareholder meeting notices and proxy materials, material agreements, shelf registration and at-the-market offering documents, private placement agreements, termination of financing arrangements and capital-structure disclosures involving ordinary shares and related securities.
Haoxi Health Technology Limited (HAO) filed its annual report on Form 20-F. The Cayman holding company operates in China through its subsidiary, providing one-stop online marketing solutions, especially short video ads, mainly for healthcare clients. It also launched livestreaming agency services in April 2025, which have not generated revenue.
The company completed an IPO at $4.00 per share, including an over-allotment, for total gross proceeds of $11,040,000. A 25-for-1 share consolidation and share capital reorganization took effect on January 10, 2025, setting authorized capital at 300,000,000 Class A and 100,000,000 Class B shares, each with $0.0025 par value. An aggregate of 2,896,595 ordinary shares were outstanding as of June 30, 2025 (2,205,795 Class A; 690,800 Class B).
The report highlights PRC regulatory risks, including CSRC filing requirements for overseas offerings. The company completed CSRC filing for its IPO in 2023 and filed regarding a follow-on in 2024. No dividends have been paid; future earnings are intended for reinvestment. Auditor Wei, Wei & Co., LLP is PCAOB-inspected, addressing HFCA Act risks noted.
Haoxi Health Technology entered a securities purchase agreement to raise capital through a private placement. On October 13, 2025, the company agreed to sell 5,217,391 Class A ordinary shares for an aggregate purchase price of approximately $1.2 million to certain non‑U.S. investors under Regulation S. The company plans to use the proceeds for working capital and general corporate purposes.
The agreement includes customary representations and warranties and is subject to various conditions to closing, including the accuracy of the parties’ representations. The shares are being offered in a transaction exempt from U.S. registration. A form of the Securities Purchase Agreement was filed as an exhibit.